<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503605</url>
  </required_header>
  <id_info>
    <org_study_id>1504-MAD-024-AR</org_study_id>
    <nct_id>NCT02503605</nct_id>
  </id_info>
  <brief_title>Biosimilar Versus Urinary Gonadotropins</brief_title>
  <acronym>BEMDON</acronym>
  <official_title>Prospective Randomized Clinical Trial to Test the Efficacy of a Biosimilar Recombinant Follicle Stimulating Hormone (FSH)vs. Urinary FSH in an Oocyte Donation Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IVI Bilbao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biosimilar drug marketing of recombinant FSH for the treatment of infertility is another step
      in simplifying fertility treatments, making them easier to manage and more accessible to
      patients. Taking in mind these arguments ,the study is proposed for determining equivalence
      in terms of biological effectiveness of an ovarian stimulation protocol with biosimilar
      recombinant FSH stimulation protocol vs. urinary FSH in oocyte donation program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biosimilar products are drugs &quot;like&quot; biotechnological origin to other innovative biological
      medicines and that can be marketed once the patent has expired. These drugs are intended to
      achieve the same therapeutic benefit as biological medicinal resembles.

      Because of the similarity in both the active substance in the formulation, it is intended to
      demonstrate the equivalence between the biosimilar medicine of recombinant FSH and FSH of
      urinary origin in terms of fitness.

      The investigators' main objective is to perform a non-inferiority trial of biosimilar
      recombinant FSH product compared to a conventional ovarian stimulation protocol with urinary
      FSH in relation to the number of oocytes retrieved and the number of metaphase II oocytes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of metaphase II oocytes</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of gonadotropins (IU)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol concentration the day of human chorionic gonadotropin (hCG) administration (picograms/mililiterl)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone concentration the day of hCG administration (nanograms/mililiter)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cryopreserved embryos</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of satisfaction (numbers 0-10)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis rate in granulosa cells</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Biosimilar recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urinary FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biosimilar recombinant FSH</intervention_name>
    <description>Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH</description>
    <arm_group_label>Biosimilar recombinant FSH</arm_group_label>
    <other_name>Bemfola</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urinary FSH</intervention_name>
    <description>Controlled ovarian stimulation with 150 IU/day urinary FSH</description>
    <arm_group_label>Urinary FSH</arm_group_label>
    <other_name>Fostipur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-35 years who meet the criteria for entry into the oocyte donor
             program and that are going to undergo controlled ovarian stimulation

        Exclusion Criteria:

          -  Patient with a basal antral count&gt; 20 follicles in total or &lt;6 antral follicles per
             ovary

          -  Patients with comorbidities that, in the opinion of the investigator, may interfere
             with the treatment of ovarian stimulation

          -  The presence of ovarian cysts that judgment of the investigator would interfere with
             the stimulation or may pose a risk to the donor

          -  BMI &lt;18 kg / m2

          -  BMI&gt; 30 kg / m2

          -  Severe hypersensitivity to drugs with similar structure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Requena, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Requena, MD, PhD</last_name>
    <phone>+31911802900</phone>
    <phone_ext>24153</phone_ext>
    <email>Antonio.Requena@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Cruz, PhD</last_name>
    <phone>+34911802900</phone>
    <phone_ext>24155</phone_ext>
    <email>Maria.Cruz@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, van der Ven K, Khalaf Y, Bentin-Ley U, Obruca A, Tews G, Schenk M, Strowitzki T, Narvekar N, Sator K, Imthurn B. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015 May;30(5):504-13. doi: 10.1016/j.rbmo.2015.01.005. Epub 2015 Jan 27.</citation>
    <PMID>25735918</PMID>
  </reference>
  <reference>
    <citation>Wolzt M, Gouya G, Sator M, Hemetsberger T, Irps C, Rettenbacher M, Vcelar B. Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. Eur J Drug Metab Pharmacokinet. 2016 Jun;41(3):259-65. doi: 10.1007/s13318-015-0257-6. Epub 2015 Jan 30.</citation>
    <PMID>25633239</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>July 17, 2015</last_update_submitted>
  <last_update_submitted_qc>July 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Antonio Requena</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Biosimilar</keyword>
  <keyword>ovarian stimulation</keyword>
  <keyword>oocyte donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

